The group’s principle activity is to provide the broadest range of synthetic DNA sequences and related services to researchers across multiple industries, including pharmaceutical and biotechnology companies. The group’s services include gene synthesis, expression optimization, and variant synthesis services. The group’s technology includes cloning. The group operates from United States.
